{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:50:21Z","timestamp":1790034621236,"version":"4.0.1"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"DOI":"10.1001\/jamaoncol.2020.4429","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T15:38:53Z","timestamp":1600961933000},"page":"e204429","source":"Crossref","is-referenced-by-count":31,"title":["Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non\u2013Small Cell Lung Cancer"],"prefix":"10.1001","volume":"6","author":[{"given":"Douglas W.","family":"Blayney","sequence":"first","affiliation":[{"name":"Stanford Cancer Institute, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Harbin Medical University Cancer Hospital, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifeng","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Bondarenko","sequence":"additional","affiliation":[{"name":"Dnipropetrovsk Medical Academy, Ukraine. Dnepropetrovsk, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihor","family":"Vynnychenko","sequence":"additional","affiliation":[{"name":"Sumy Regional Clinical Oncology Dispensary, Sumy State University, Sumy, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadezhda","family":"Kovalenko","sequence":"additional","affiliation":[{"name":"Volgograd Regional Clinical Oncology Dispensary, Volgograd, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Nair","sequence":"additional","affiliation":[{"name":"Mid Florida Hematology and Oncology Center, Orange City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Redlands Community Hospital, Redlands, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitriy Petrovich","family":"Udovista","sequence":"additional","affiliation":[{"name":"SBI of Healthcare Oncology Dispensary No. 2, Ministry of Health of Krasnodar Region, Sochi, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Mohanlal","sequence":"additional","affiliation":[{"name":"BeyondSpring Pharmaceuticals, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Ogenstad","sequence":"additional","affiliation":[{"name":"Statogen Consulting, Wake Forest, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ene","family":"Ette","sequence":"additional","affiliation":[{"name":"Anoixis Corporation, Natick, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Du","sequence":"additional","affiliation":[{"name":"Wanchun Bulin Pharmaceuticals Limited, Dalian, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Huang","sequence":"additional","affiliation":[{"name":"BeyondSpring Pharmaceuticals, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-kai","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"},{"name":"Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,11,12]]},"reference":[{"issue":"18","key":"coi200070r1","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1056\/NEJM199305063281808","article-title":"Management of fever in patients with cancer and treatment-induced neutropenia.","volume":"328","author":"Pizzo","year":"1993","journal-title":"N Engl J Med"},{"issue":"3","key":"coi200070r2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.","volume":"325","author":"Crawford","year":"1991","journal-title":"N Engl J Med"},{"issue":"6","key":"coi200070r3","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/annonc\/mdf130","article-title":"Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.","volume":"13","author":"Holmes","year":"2002","journal-title":"Ann Oncol"},{"issue":"9","key":"coi200070r4","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1093\/annonc\/mdv281","article-title":"Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.","volume":"26","author":"Blackwell","year":"2015","journal-title":"Ann Oncol"},{"key":"coi200070r5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2147\/CEOR","article-title":"Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar.","volume":"10","author":"Schwartzberg","year":"2018","journal-title":"Clinicoecon Outcomes Res"},{"issue":"6","key":"coi200070r6","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s00432-018-2643-3","article-title":"A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.","volume":"144","author":"Waller","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"issue":"15","key":"coi200070r7","doi-asserted-by":"publisher","first-page":"21693","DOI":"10.1200\/JCO.2017.35.15_suppl.e21693","article-title":"Randomized, single-blind, crossover study to assess the pharmacokinetic and pharmacodynamic bioequivalence of CHS-1701 to pegfilgrastim in healthy subjects.","volume":"35","author":"Glaspy","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"coi200070r8","doi-asserted-by":"publisher","first-page":"540","DOI":"10.6004\/jnccn.2005.0030","article-title":"Myeloid growth factors clinical practice guidelines in oncology.","volume":"3","author":"Crawford","year":"2005","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"coi200070r9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.3816\/CBC.2003.n.003","article-title":"Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer.","volume":"3","author":"Kubista","year":"2003","journal-title":"Clin Breast Cancer"},{"issue":"9","key":"coi200070r10","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1177\/1060028017706373","article-title":"Pegfilgrastim-induced bone pain: a review on incidence, risk factors, and evidence-based management.","volume":"51","author":"Moore","year":"2017","journal-title":"Ann Pharmacother"},{"issue":"11","key":"coi200070r11","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1016\/j.chempr.2019.08.022","article-title":"Structure, thermodynamics, and kinetics of plinabulin binding to two tubulin isotypes.","volume":"5","author":"La Sala","year":"2019","journal-title":"Chem"},{"issue":"23","key":"coi200070r12","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.1158\/1078-0432.CCR-10-1096","article-title":"Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas.","volume":"16","author":"Mita","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"3","key":"coi200070r13","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s10637-011-9642-4","article-title":"Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel.","volume":"30","author":"Millward","year":"2012","journal-title":"Invest New Drugs"},{"issue":"2","key":"coi200070r14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00280-019-03998-w","article-title":"Plinabulin ameliorates neutropenia induced by multiple chemotherapies through a mechanism distinct from G-CSF therapies.","volume":"85","author":"Tonra","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"coi200070r15","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.6004\/jnccn.2017.0175","article-title":"Myeloid growth factors, version 2.2017, NCCN Clinical Practice Guidelines in Oncology.","volume":"15","author":"Crawford","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"coi200070r16","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory.","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singapore"},{"issue":"2","key":"coi200070r18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/ajco.2014.10.issue-2","article-title":"Minimal important differences in the EORTC QLQ-C30 in patients with advanced cancer.","volume":"10","author":"Bedard","year":"2014","journal-title":"Asia Pac J Clin Oncol"},{"issue":"8","key":"coi200070r19","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jclinepi.2015.02.011","article-title":"Summary scores captured changes in subjects\u2019 QoL as measured by the multiple scales of the EORTC QLQ-C30.","volume":"68","author":"Phillips","year":"2015","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"coi200070r21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1023\/A:1023573429626","article-title":"Mechanistic models for myelosuppression.","volume":"21","author":"Friberg","year":"2003","journal-title":"Invest New Drugs"},{"issue":"2514","key":"coi200070r22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1126\/science.97.2514.209","article-title":"Opportunities in mathematical statistics, with special reference to sampling and quality control.","volume":"97","author":"Deming","year":"1943","journal-title":"Science"},{"issue":"3","key":"coi200070r23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s002800050892","article-title":"Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial.","volume":"43","author":"Alexopoulos","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"coi200070r24","doi-asserted-by":"publisher","first-page":"S647","DOI":"10.1016\/j.jtho.2019.08.1367","article-title":"P2.01-23 DUBLIN-3, a phase (Ph) III trial comparing the plinabulin (P)\/docetaxel(D) combination with docetaxel alone in stage IIIb\/IV NSCLC.","volume":"14","author":"Mohanlal","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"3","key":"coi200070r25","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1177\/1078155215585188","article-title":"Pegfilgrastim use and bone pain: a cohort study of community-based cancer patients.","volume":"22","author":"Pawloski","year":"2016","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"coi200070r26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.critrevonc.2013.08.006","article-title":"The five \u201cWs\u201d for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs).","volume":"89","author":"Lambertini","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"coi200070r17","volume-title":"The Brief Pain Inventory User Guide.","author":"Cleeland","year":"2009"},{"key":"coi200070r20","volume-title":"EORTC QLQ-C30 Reference Values and Bibliography","author":"EORTC Quality of Life Group","year":"2002"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2770700\/jamaoncology_blayney_2020_oi_200070_1604947267.93225.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T17:44:20Z","timestamp":1605203060000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2770700"}},"subtitle":["A Phase 2 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,11,12]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2020.4429","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,12]]}}}